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OBJECTIVES—Genome-wide association studies have dramat-
ically increased the number of common genetic variants that are
robustly associated with type 2 diabetes. A possible clinical use
of this information is to identify individuals at high risk of
developing the disease, so that preventative measures may be
more effectively targeted. Here, we assess the ability of 18
conﬁrmed type 2 diabetes variants to differentiate between type
2 diabetic case and control subjects.
RESEARCH DESIGN AND METHODS—We assessed index
single nucleotide polymorphisms (SNPs) for the 18 independent
loci in 2,598 control subjects and 2,309 case subjects from the
Genetics of Diabetes Audit and Research Tayside Study. The
discriminatory ability of the combined SNP information was
assessed by grouping individuals based on number of risk alleles
carried and determining relative odds of type 2 diabetes and by
calculating the area under the receiver-operator characteristic
curve (AUC).
RESULTS—Individuals carrying more risk alleles had a higher
risk of type 2 diabetes. For example, 1.2% of individuals with 24
risk alleles had an odds ratio of 4.2 (95% CI 2.11–8.56) against the
1.8% with 10–12 risk alleles. The AUC (a measure of discrimina-
tive accuracy) for these variants was 0.60. The AUC for age, BMI,
and sex was 0.78, and adding the genetic risk variants only
marginally increased this to 0.80.
CONCLUSIONS—Currently, common risk variants for type 2
diabetes do not provide strong predictive value at a population
level. However, the joint effect of risk variants identiﬁed sub-
groups of the population at substantially different risk of disease.
Further studies are needed to assess whether individuals with
extreme numbers of risk alleles may beneﬁt from genetic testing.
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R
ecent genome-wide association (GWA) studies,
which assay 300,000 single nucleotide poly-
morphisms (SNPs) across many thousands of
individuals, have led to the discoveries of vari-
ants predisposing to many common complex diseases,
including type 2 diabetes (1–6), coronary artery disease
(7–9), prostate cancer (10,11), Crohn’s disease (12–14),
and many others (see http://www.genome.gov/26525384
for an up to date list of all GWA studies). The variants
identiﬁed by these GWA studies are common in the
general population (minor allele frequency 1%), but most
have, individually, only small effects on disease risk, with
odds ratios (ORs) typically 1.3.
Despite the relatively small predisposing effects con-
ferred, these variants provide important, novel insights
into disease biology. For example, variants of a number of
genes, such as HHEX, CDKN2A/B, and CDKAL1, impli-
cate defects in pancreatic -cell development and function
as important in type 2 diabetes etiology (4,15,16), whereas
the discovery that variants in FTO are associated with BMI
opened up novel areas of investigation for obesity biology
(17–19). By gaining further knowledge of the underlying
biology, and promoting potential therapeutic and preven-
tative approaches, these insights are likely to be the most
important outcome from these GWA studies.
A more immediate clinical utility may be to use the
identiﬁed risk variants to aid the determination of an individ-
ual’s risk of developing a particular disease. Several compa-
nies, such as deCODE genetics and 23andme, have begun to
use SNPs identiﬁed from these GWA studies, offering up to 1
million SNP GWA scans (http://www.decodeme.com; https://
www.23andme.com) or individual disease-associated SNP
tests (http://www.decodediagnostics.com). It is, however,
unclear how useful the currently identiﬁed variants will be in
predicting disease.
One of the disease traits for which the GWA approach
has been most successful is type 2 diabetes. Together with
candidate gene approaches, 18 common variants, includ-
ing FTO and two independent signals in the CDKN2A/B
region, have now been convincingly shown to associate
with the disease (1–6,20–26). In this study, we aimed to
assess the combined discriminatory power of these com-
mon, modest effect variants, using 4,900 individuals from
the Genetics of Diabetes Audit and Research Tayside
Study (GoDARTS).
RESEARCH DESIGN AND METHODS
SNP selection and genotyping. We only included variants that have been
convincingly shown to associate with type 2 diabetes. We used variants
reviewed by Frayling (27) and those described by Zeggini et al. (5,6), except
for the E23K (rs5219; r
2 with GWA-SNP rs5215  0.89) variant of KCNJ11 (22)
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2 with GWA-SNP rs7901695  0.80) of TCF7L2 (23,28), where
we genotyped a SNP shown to have stronger association with type 2 diabetes,
but which were not genotyped on the genome-wide association chips; the
TCF2 locus, where we used rs757210 (26), instead of rs4430796 (24) (r
2 
0.61); and the ADAM30/NOTCH2 locus, where we used rs2641348 in ADAM30
as a proxy for rs2934381 (r
2  0.92).
Genotyping was performed by KBioscience (Hertsfordshire, U.K.), which
designed and used assays based on either their proprietary competitive
allele-speciﬁc PCR (KASPar) method or a modiﬁed TaqMan-based assay,
details of which are available on the company website (www.kbioscience.
co.uk/chemistry/index.htm). Genotyping quality control measures for the
SNPs are as described previously (5,6,25).
GoDARTS study and participants. The GoDARTS study is a substudy of the
Diabetes Audit and Research Tayside Study (DARTS) (29), which aims to
identify all known diabetes patients in the Tayside region of Scotland using
electronic database retrieval. The samples used in this study are a subsample
of the type 2 diabetes patients identiﬁed and have been described in detail
previously (6). Brieﬂy, the GoDARTS study includes individuals of white
European descent, living in the Tayside region when recruited. The diagnosis
of diabetes in case subjects was based on either current treatment with
diabetes-speciﬁc medication or laboratory evidence of hyperglycemia if
treated with diet alone. Patients with conﬁrmed diagnosis of monogenic
diabetes and those treated with regular insulin therapy within 1 year of
diagnosis were excluded. Case subjects in this study had an age at diagnosis
between 35 and 70 years, inclusive. Control subjects had not been diagnosed
with diabetes at the time of recruitment or subsequently and were excluded if
there was evidence of hyperglycemia during recruitment (fasting glucose 7.0
mmol/l, A1C 6.4%) or if they were 80 years old. The study was approved by
the Tayside Medical Ethics Committee. Informed consent was obtained from
all study participants. Table 1 presents the clinical characteristics of subjects
used in this study.
Statistical analysis. All statistical analyses were performed in StataSE v10.0
for Windows (StataCorp, Brownsville, TX). We used logistic regression for all
individual SNP analyses. To test for deviation from a within-loci additive
model, we performed likelihood ratio test of an additive model against a
general 2 degrees of freedom model. To test for gene-gene interaction across
all pairs of loci, we used likelihood ratio tests to compare an additive model
to a model with an interaction term. We combined information from multiple
SNPs by using an allele count model, where we summed the number of risk
alleles carried by each individual. This assumes that each of the alleles has an
equal and additive effect on type 2 diabetes risk.
We used logistic regression on the general model (i.e., individual SNP
genotypes as indicator variables) to construct the receiver-operating charac-
teristic (ROC) curves and calculate the areas under the curve (AUCs). We also
performed these ROC analyses on the allele count model for comparison with
the general model.
RESULTS
Genotyping data on all of the variants were available for
2,309 type 2 diabetic case subjects and 2,598 control
subjects. Characteristics of these participants are shown
in Table 1. Supplementary Table 1, available in an online
appendix at http://dx.doi.org/10.2337/db08-0504, presents a
comparison of clinical characteristics for these subjects
against the 1,739 who were not successfully genotyped
across all SNPs. Individually, the variants have similar
effect sizes in this study compared with those reported in
other large studies (Table 2) (1–6,20–26), and the range of
ORs from 1.00 to 1.36 most likely reﬂects stochastic
variation. Several variants are not associated at P  0.05 in
the sample used here but are still included in the analyses
because they are conﬁrmed type 2 diabetes risk variants,
and the lack of signiﬁcance is the result of relatively low
power in this number of subjects. Based on these and
larger datasets, all of the variants appear to have an
additive mode of inheritance (1–6,20–26). The CDKAL1
locus was reported by Steinthorsdottir et al. (4) to ﬁt a
recessive model, but other large studies do not support
this. There is no evidence of interaction between any of
the SNPs based on these data (supplementary Table 2) or
on the larger analyses previously published. Therefore, we
assumed an additive genetic model. We found no evidence
TABLE 1







Men (%) 56 51
Age at diagnosis (years) 55.7  9.0 NA
BMI (kg/m
2) 31.5  6.1 26.9  4.5
A1C 7.8  1.5 5.5  0.3
Data are n, percent, and means  SD.
TABLE 2





test P value OR (95% CI) P value
rs7903146 TCF7L2 0.30 0.70 1.36 (1.24–1.48) 3.97  10
12
rs5219 KCNJ11 0.36 0.058 1.25 (1.15–1.36) 8.54  10
8
rs10811661 CDKN2A/2B 0.85 0.24 1.21 (1.08–1.35) 8.82  10
4
rs1801282 PPARG 0.87 0.46 1.21 (1.07–1.36) 2.18  10
3
rs2641348* ADAM30/NOTCH2 0.11 0.68 1.15 (1.01–1.30) 3.20  10
2
rs564398 CDKN2A/2B 0.59 0.95 1.13 (1.04–1.22) 3.61  10
3
rs4402960 IGF2BP2 0.33 0.76 1.12 (1.03–1.22) 7.62  10
3
rs8050136 FTO 0.41 0.32 1.11 (1.02–1.20) 1.43  10
2
rs10946398 CDKAL1 0.34 0.19 1.11 (1.02–1.21) 1.47  10
2
rs13266634 SLC30A8 0.70 0.60 1.10 (1.01–1.20) 2.57  10
2
rs7961581 TSPAN8/LGR5 0.29 0.87 1.09 (1.00–1.19) 5.56  10
2
rs12779790 CDC123 0.20 0.15 1.10 (0.99–1.21) 7.58  10
2
rs10010131 WFS1 0.60 0.54 1.07 (0.99–1.16) 9.19  10
2
rs757210 TCF2 0.37 0.18 1.07 (0.99–1.16) 1.09  10
1
rs4607103 ADAMTS9 0.77 0.60 1.05 (0.96–1.16) 2.89  10
1
rs1111875 HHEX-IDE 0.62 0.19 1.02 (0.94–1.11) 5.98  10
1
rs7578597 THADA 0.91 0.33 1.04 (0.90–1.19) 6.07  10
1
rs864745 JAZF1 0.50 0.50 1.00 (0.93–1.09) 9.70  10
1
Only samples that were successfully genotyped for all 18 variants are included. Additive model test P value refers to a test of deviation from
additivity of alleles at each SNP. *This SNP falls within the ADAM30 gene and is a proxy (r
2  0.92 in HapMap CEU) for rs2934381 in the
NOTCH2 gene, which showed stronger association previously (5).
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or age (lowest interaction P values  0.14 and 0.02,
respectively). We performed the analysis with and without
the FTO variant, the one variant shown to predispose to
type 2 diabetes through a primary effect on BMI (18).
Comparing extremes. The proportion of case and con-
trol subjects grouped according to the number of risk
alleles that they carry is shown in Fig. 1. The distribution
of risk alleles follows a normal distribution in both case
and control subjects, with a shift toward a higher number
of risk alleles in the case subjects. There is an increase in
ORs for type 2 diabetes with the increasing number of risk
alleles against the baseline group of 1.8% of individuals
carrying 10–12 risk alleles. Of individuals with 25 risk
alleles, 1.2% have an OR of 4.2 (95% CI 2.11–8.56) against
the baseline reference group. Similarly, 11.5% of this study
population carrying 22 risk alleles had an OR of 2.3
(1.73–2.93) for type 2 diabetes compared with the 8.2% of
individuals with 14 risk alleles.
Figure 2 plots the ORs relative to the median number of
18 risk alleles. Those with 25 risk alleles were more than
twice as likely to have type 2 diabetes (OR 2.18 [95% CI
1.24–3.81]) compared with those with the median number
of risk alleles. The TCF7L2 variant had a stronger effect
than the other variants (OR 1.36 compared with 1.00–1.25
for the rest), so these results may be slight underestimates,
because the additive model used for the allele counting
assumes equal effects across all SNPs.
We performed the same analyses for two subgroups of
the cohort, one including only obese individuals (with BMI
of 30 kg/m
2, n  1,803), the other nonobese individuals
(BMI 30 kg/m
2, n  3,083). The results were similar across
these subgroups. For example, the 1.4% of obese individuals
with 24 risk alleles had an OR of 5.5 (95% CI 2.11–14.36)
compared with the 1.9% of obese individuals with 13 risk
alleles. The corresponding OR for the nonobese subjects was
3.31 (1.34–8.16), for the 1.8 and 1.1% of individuals with 13
and 24 risk alleles, respectively.
ROC curve. We evaluated the discriminatory power of a
genetic test based on the 18 type 2 diabetes variants by
calculating the area under the ROC curve. Using the
general model (as opposed to the additive model, which
assumes equal and additive effects), the ROC curve for the
18 type 2 diabetes variants studied here is 0.60 (Fig. 3). We
performed the same analysis for the obese and nonobese
subgroups of the cohort. The AUCs for the obese and
nonobese groups were 0.58 and 0.60, respectively. A
similar result was obtained when we removed the FTO
variant (obese, 0.58; nonobese, 0.59). We also tested
whether the risk variants would add to the discriminatory
power of BMI, age, and sex alone (AUC 0.78 in our study).
A model that includes BMI, age, sex, and the 18 variants
has an AUC of 0.80 (Fig. 3); although marginal, the
increase in the AUC was statistically signiﬁcant (P 
2.88  10
12). The AUC remained virtually the same
(AUC  0.80) when the FTO variant was removed from the
model.
The effect of BMI and age. Supplementary Table 3
presents the individual SNP type 2 diabetes associations
adjusted for BMI. As expected, the FTO association is
weakened on adjusting for BMI (OR 1.00 [95% CI 0.92–
1.10]), and the TCF7L2 association is strengthened (1.46
[1.32–1.61]). Testing the combined effect of the risk vari-
ants on clinical features of the type 2 diabetes patients, we
found that the number of risk alleles was associated with
an earlier age at diagnosis of 0.15 years per risk allele (95%
CI 0.29 to 0.01, P  0.038). We also observed an overall
modifying effect on BMI (0.14 BMI units per risk allele
[0.23 to 0.05], P  3.41  10
3), but this ﬁnding is
mainly explained by the known association of the TCF7L2
variant alone with BMI in type 2 diabetic case subjects
(30,31). Here, each TCF7L2 risk allele was associated with
a difference in BMI of 0.69 kg/m
2 (1.06 to 0.31, P 
3.18  10
4), whereas the combined effect of all other
variants without TCF7L2 could just be detected (0.10
kg/m
2 per risk allele [0.20 to 0.01], P  0.036). The
difference in BMI and age at diagnosis was more notice-
able when we compared individuals with low and high
numbers of risk alleles. For example, carriers of 23 risk
alleles (11.8%) were, on average, diagnosed 4.2 years
FIG. 1. Distribution of risk alleles in type 2 diabetic case subjects (black bars) and control subjects (gray bars).
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4) and had 1.60
kg/m
2 lower BMI (3.35 to 0.08, P  0.062) than those
carrying 15 (8.6%) risk alleles.
DISCUSSION
Recent success in identifying common variants predispos-
ing to type 2 diabetes has led to suggestions that they may
be useful in predicting an individual’s risk of the disease.
In this study, we evaluated the ability of 18 conﬁrmed
predisposing variants to discriminate between individuals
with and without type 2 diabetes, using the GoDARTS
study. The samples used in this study were not enriched
for family history or low BMI, factors that may inﬂate
effect sizes. Although the GoDARTS cohort was a part of
the Wellcome Trust Case Control Consortium-Type 2
Diabetes GWA Study (5,6), it was only used as a stage 2
replication set for the follow-up of the initial hits. This
means that there should be a minimal effect of the
“winner’s curse” (32), the upward bias of the effect size in
the discovery samples compared with subsequent replica-
tion studies.
The combined information identiﬁes individuals at
different risks of disease. By comparing individuals
with the fewest type 2 diabetes risk alleles with those
carrying the most risk alleles, combining genetic informa-
tion allowed us to identify subgroups of the population at
a distinctly differing risk of disease. For example, we were
able to distinguish 1% of the population carrying 25
risk alleles that had more than four times increased risk of
diabetes compared with the 2% with 10–12 risk alleles. The
high-risk group also had over twice the odds for type 2
diabetes than those with the median number of risk
alleles. These ﬁgures were similar in individuals who were
obese and not obese, a major risk factor for type 2 diabetes
and easily measurable. Obese individuals carrying large
numbers of type 2 diabetes risk alleles may therefore be a
particular group worth studying to test potential interven-
tion strategies. This may be important given that the
escalating rates of obesity and type 2 diabetes suggest that
efforts aimed at the whole population are not effective and
that intensive, but expensive, lifestyle interventions aimed
at increasing exercise and improving diet can result in
weight loss and a reduced risk of type 2 diabetes (33–36).
The current variants are not particularly discrimina-
tive but explain only a small amount of the heritabil-
ity of type 2 diabetes. Rather than focusing on in-
dividuals with “extreme” numbers of risk alleles, at a
population level, the utility of genetic tests may be better
classiﬁed by ROC curves. One of the most important
factors in the validity of a genetic test in clinical practice
is its ability to discriminate between individuals who will
and will not develop the disease. A clinically relevant AUC
threshold clearly depends on a whole range of factors (for
FIG. 2. A plot showing the increasing ORs with the increasing number of type 2 diabetes risk alleles versus the baseline of 10–11 risk alleles. The
ORs are given relative to the median number of 18 risk alleles (F). The vertical bars represent 95% CIs.
FIG. 3. ROC plot for a model containing all type 2 diabetes variants,
BMI, age, and sex (gray line, AUC  0.80) and for the 18 variants alone
(black line, AUC  0.60).
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preventative measures), but as an example from current
clinical practice, oxidized-LDL cholesterol has an AUC of
0.80 for coronary artery disease (37), making it a good
discriminator between patients and healthy control sub-
jects. The 18 type 2 diabetes variants had an inadequate
discriminatory ability with an AUC of 0.60, a slight im-
provement on the AUC of 0.55 based on TCF7L2 alone.
These data imply that genetic tests for type 2 diabetes (and
many other complex diseases) that are offered by several
commercial companies currently have limited predictive
value. However, there are many more variants to be
identiﬁed, because these 18 variants only explain a small
amount of the heritability of type 2 diabetes: the sibling
relative risk for type 2 diabetes is 3 (38), and the
combination of these variants would only account for a
sibling relative risk of 1.07. As more susceptibility vari-
ants are found for type 2 diabetes, genetic testing that uses
the inexpensive and rapid genotyping technologies may
eventually become more clinically useful.
The use of genetic information in addition to age,
sex, and BMI. For many complex diseases, there are
already well-established risk factors that can be used to
predict someone’s chances of developing the disease.
Incorporating genetic information may be justiﬁed on the
basis that current preventative measures are expensive
and that prevention at a population level is not effective, so
the more selective we can be the better. In type 2 diabetes,
family history, age, BMI, ethnicity, and lifestyle all contrib-
ute to an individual’s risk of the disease. In our study, the
AUC for BMI, age, and sex (we did not have family history
data) combined was 0.78, a moderate diagnostic value.
The genetic risk variants had a poor discriminatory ability
alone (AUC  0.60) and only marginally increased the
discriminatory power of the test when combined with
BMI, age, and sex (AUC  0.80), suggesting that they add
little to the already known predictive factors.
Risk variants modify clinical characteristics of indi-
viduals with type 2 diabetes. Type 2 diabetes often
occurs in individuals who are not overweight or obese,
and can be diagnosed at a relatively young age. This may
be because these individuals have a stronger genetic risk
component than more “typical” type 2 diabetes patients.
Therefore, we tested the extent to which patients with the
stronger genetic predisposition tended to be leaner, and
how much younger they were at diagnosis. There were
notable differences between the 11.8 and 8.6% of the
population carrying either high or low numbers of disease-
predisposing alleles, respectively. Patients with high ge-
netic risk had an average BMI of 30.3 kg/m
2 compared with
31.9 kg/m
2 in those with low genetic risk and were
diagnosed at an average age of 55.2 years, compared with
59.3 years for patients with relatively low genetic risk.
These results support an important role for genetic pre-
disposition to type 2 diabetes in nonobese, young-onset
case subjects.
Weighting variants and the optimal ROC curve. The
simple allele count model we used for some of our
analyses of “extremes” assumes that each risk allele has
the same effect size and that the effects are additive both
within and between loci. Although we found no strong
evidence for deviation from additivity, clearly some SNPs
have stronger effects than others. This is most evident for
TCF7L2, where the allelic OR is 1.37, signiﬁcantly larger
than any of the other variants. One way to overcome this
is to weigh SNPs differently; however, we decided not to
do this in this study for a number of reasons. First, all of
our AUC analyses are based on a general model, in which
the assumption of equal effects is not made. Second, as
Janssens et al. (39) previously showed, when the ORs of
the individual variants are relatively low (as here), there is
little difference in the discriminative accuracy of the test
based on the simple allele count model and a model that
allows each variant to have a different effect size (the
AUCs here are 0.583 and 0.603, respectively, although this
was statistically signiﬁcant [P  0.001]). Third, it is unclear
what the most appropriate weights to use would be.
Fourth, an allele count model provides important advan-
tages for simplicity and visualization of the results.
Recently, Lu and Elston (40) proposed using an optimal
ROC analysis approach rather than the standard approach
that we have used. Although the authors proved theoreti-
cally that their method is more powerful, the results
presented by Lu and Elston (40) showed that the two
methods produce the same results when there are few loci
and no interactive effects. Because we still have only a
relatively few loci, there is no evidence of any nonadditive
effects within or between loci, and the ROC curve is
concave (40), the two methods should produce the same
results. We tested this using the 10 SNPs that were
signiﬁcant (at P  0.05) in our study. Using these variants,
the results were the same for both methods (AUC for the
Lu and Elston method, 0.596; AUC for the standard
method, 0.596).
Strengths and limitations of our study. Our study was
relatively large in terms of the number of samples, and the
number of common variants used. We had 2,000 case
subjects and 2,000 control subjects after excluding indi-
viduals who were not successfully genotyped for all of the
variants included in the study. The 18 variants we used had
all been convincingly shown in previous studies to asso-
ciate with type 2 diabetes.
One of the main limitations of our study is that it was
not prospective, and therefore, we are unable to truly
determine the predictive power of these variants. Al-
though the results of this study only apply to the Tayside
population, it is likely, based on previous data (41–43),
that our prediction estimates are reasonably accurate and
that the effect sizes observed are likely to be representa-
tive of those in similar populations. A second limitation is
that although the results are applicable to the Tayside and
similar populations, they may not apply to populations of
substantially different ethnic origin or those exposed to
different social and environmental circumstances. A third
limitation concerns the caveat that the majority of the type
2 diabetes–associated SNPs identiﬁed to date and used in
this study are not the causal variants. This means that the
predictive power of these susceptibility loci is likely to be
an underestimate. Fine mapping and sequencing ap-
proaches are needed to identify the variants causal to
these associations, which often have stronger effects than
the currently identiﬁed variants. These follow-up studies
may also reveal additional causal variants at these loci that
cannot be detected by GWA methods because of, for
example, low frequency, but that may have higher pen-
etrance and therefore would be much more powerful
predictors.
In conclusion, the combined information from the cur-
rently known susceptibility variants allows us to identify
subgroups of the population at substantially increased
odds of getting type 2 diabetes. These individuals could be
targeted with more effective preventative measures. On a
H. LANGO AND ASSOCIATES
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in discriminating between individuals who will and will
not develop type 2 diabetes. As more variants are identi-
ﬁed, tests with better predictive performance should be-
come available and could eventually become a valuable
addition to clinical practice.
ACKNOWLEDGMENTS
M.N.W. is a Vandervell Foundation Research Fellow. E.Z.
is a Wellcome Trust Research Career Development Fel-
low. This work has received funding from Wellcome Trust.
We thank all study participants.
REFERENCES
1. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PIW, Chen H, Roix
JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler
D, Almgren P, Florez JC, Meyer J, Ardlie K, Bostrom KB, Isomaa B, Lettre
G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-
Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C,
Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila
E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R,
Blumenstiel B, Parkin M, DeFelice M, Barry R, Brodeur W, Camarata J,
Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C,
Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma QC, Parikh H,
Richardson D, Ricke D, Purcell S: Genome-wide association analysis
identiﬁes loci for type 2 diabetes and triglyceride levels. Science 316:1331–
1336, 2007
2. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR,
Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift
AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL,
Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW,
Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM,
Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN,
Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of
type 2 diabetes in Finns detects multiple susceptibility variants. Science
316:1341–1345, 2007
3. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent
D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ,
Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D,
Polychronakos C, Froguel P: A genome-wide association study identiﬁes
novel risk loci for type 2 diabetes. Nature 445:881–885, 2007
4. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R,
Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V,
Ghosh S, Baker A, Snorradottir S, Bjarnason H, Ng MCY, Hansen T, Bagger
Y, Wilensky RL, Reilly MP, Adeyemo A, Chen YX, Zhou J, Gudnason V,
Chen GJ, Huang HX, Lashley K, Doumatey A, So WY, Ma RCY, Andersen G,
Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH,
Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JCN,
Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong A,
Stefansson K: A variant in CDKAL1 inﬂuences insulin response and risk of
type 2 diabetes. Nat Genet 39:770–775, 2007
5. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker
PIW, Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostrom KB,
Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines
PS, Daly MJ, Deodhar P, Ding C-J, Doney ASF, Duren WL, Elliott KS, Erdos
MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ,
Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B,
Jackson AU, Jorgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J,
Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V,
Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD,
Narisu N, Nilsson P, Owen KR, Palmer CNA, Payne F, Perry JRB, Pettersen
E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ,
Sandbaek A, Shields B, Sjogren M, Steinthorsdottir V, Stringham HM, Swift
AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto
J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Illig T, Hveem K, Hu
FB, Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso I,
Hattersley AT, Collins FS, Groop L, McCarthy MI, Boehnke M, Altshuler D:
Meta-analysis of genome-wide association data and large-scale replication
identiﬁes additional susceptibility loci for type 2 diabetes. Nat Genet
40:638–645, 2008
6. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H,
Timpson NJ, Perry JRB, Rayner NW, Freathy RM, Barrett JC, Shields B,
Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight
B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney ASF, McCarthy MI,
Hattersley AT: Replication of genome-wide association signals in UK
samples reveals risk loci for type 2 diabetes. Science 316:1336–1341, 2007
7. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T,
Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G,
Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM,
Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S,
Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H,
Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteins-
dottir U, Kong A, Stefansson K: A common variant on chromosome 9p21
affects the risk of myocardial infarction. Science 316:1491–1493, 2007
8. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR,
Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E,
Hobbs HH, Cohen JC: A common allele on chromosome 9 associated with
coronary heart disease. Science 316:1488–1491, 2007
9. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B,
Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR,
Stevens SE, Szymczak S, Tregouet D, Iles MM, Pahlke F, Pollard H, Lieb W,
Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ,
Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD,
Ziegler A, Thompson JR, Schunkert H: Genomewide association analysis
of coronary artery disease. New Engl J Med 357:443–453, 2007
10. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson
D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A,
Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu JF, Blondal T, Kostic
J, Sun JL, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM,
Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Marcos JGI, Walsh
PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J,
Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson
E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ,
Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K:
Genome-wide association study identiﬁes a second prostate cancer sus-
ceptibility variant at 8q24. Nat Genet 39:631–637, 2007
11. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello
MJ, Fearnhead P, Yu K, Chatterjee N, Wang ZM, Welch R, Staats BJ, Calle
EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein
S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot
O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni
JF, Hoover R, Hunter DJ, Chanock SJ, Thomas G: Genome-wide associa-
tion study of prostate cancer identiﬁes a second risk locus at 8q24. Nat
Genet 39:645–649, 2007
12. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M,
Mayr G, De La Vega FM, Briggs J, Gunther S, Prescott NJ, Onnie CM,
Hasler R, Sipos B, Folsch UR, Lengauer T, Platzer M, Mathew CG,
Krawczak M, Schreiber S: A genome-wide association scan of nonsynony-
mous SNPs identiﬁes a susceptibility variant for Crohn disease in
ATG16L1. Nat Genet 39:207–211, 2007
13. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA,
Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW,
Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM,
McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes
A, Sanderson J, Jewell DP, Satsangi J, Mansﬁeld JC, Cardon L, Mathew CG:
Sequence variants in the autophagy gene IRGM and multiple other
replicating loci contribute to Crohn’s disease susceptibility. Nat Genet
39:830–832, 2007
14. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green
T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Grifﬁths AM, Targan SR,
Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP,
Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR: Genome-
wide association study identiﬁes new susceptibility loci for Crohn disease
and implicates autophagy in disease pathogenesis. Nat Genet 39:596–604,
2007
15. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A,
Clausen JO, Rasmussen SS, Jorgensen T, Sandbaek A, Lauritzen T, Schmitz
O, Hansen T, Pedersen O: Studies of association of variants near the
HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired
insulin release in 10,705 Danish subjects: validation and extension of
genome-wide association studies. Diabetes 56:3105–3111, 2007
16. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, Weedon
MN, Mari A, Hattersley AT, McCarthy MI, Frayling TM, Walker M: Common
variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are
associated with decreased pancreatic -cell function. Diabetes 56:3101–
3104, 2007
17. Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, Carlsson
LMS, Kiess W, Vatin V, Lecoeur C, Delplanque J, Vaillant E, Pattou F, Ruiz
J, Weill J, Levy-Marchal C, Horber F, Potoczna N, Hercberg S, Le Stunff C,
Bougneres P, Kovacs P, Marre M, Balkau B, Cauchi S, Chevre JC, Froguel
IMPACT OF 18 VARIANTS ON TYPE 2 DIABETES RISK
3134 DIABETES, VOL. 57, NOVEMBER 2008P: Variation in FTO contributes to childhood obesity and severe adult
obesity. Nat Genet 39:724–726, 2007
18. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren
CM, Perry JRB, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW,
Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S,
Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ,
Melzer D, Ferrucci L, Loos RJF, Barroso I, Wareham NJ, Karpe F, Owen
KR, Cardon LR, Walker M, Hitman GA, Palmer CNA, Doney ASF, Morris
AD, Smith GD, Hattersley AT, McCarthy MI: A common variant in the FTO
gene is associated with body mass index and predisposes to childhood and
adult obesity. Science 316:889–894, 2007
19. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja
R, Orru M, Usala G, Dei M, Lai S, Maschio A, Busonero F, Mulas A, Ehret
GB, Fink AA, Weder AB, Cooper RS, Galan P, Chakravarti A, Schlessinger
D, Cao A, Lakatta E, Abecasis GR: Genome-wide association scan shows
genetic variants in the FTO gene are associated with obesity-related traits.
PLoS Genet 3:1200–1210, 2007
20. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C,
Nemesh J, Lane CR, Schaffner F, Bolk S, Brewer C, Tuomi T, Gaudet D,
Hudson TJ, Daly M, Groop L, Lander ES: The common PPAR	 Pro12Ala
polymorphism is associated with decreased risk of type 2 diabetes. Nat
Genet 26:76–80, 2000
21. Florez JC, Burtt N, de Bakker PI, Almgren P, Tuomi T, Holmkvist J, Gaudet
D, Hudson TJ, Schaffner SF, Daly MJ, Hirschhorn JN, Groop L, Altshuler D:
Haplotype structure and genotype-phenotype correlations of the sulfonyl-
urea receptor and the islet ATP-sensitive potassium channel gene region.
Diabetes 53:1360–1368, 2004
22. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G,
Walker M, Levy JC, Sampson M, Halford S, McCarthy MI, Hattersley AT,
Frayling TM: Large-scale association studies of variants in genes encoding
the pancreatic -cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1
(ABCC8) conﬁrm that the KCNJ11 E23K variant is associated with type 2
diabetes. Diabetes 52:568–572, 2003
23. Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A,
Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkars-
dottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gud-
mundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP,
Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thor-
steinsdottir U, Gulcher JR, Kong A, Stefansson K: Variant of transcription
factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet
38:320–323, 2006
24. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifs-
son G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A,
Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN,
Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B,
Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K,
Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A,
Chen Y, Zhou J, So WY, Tong PCY, Ng MCY, Hansen T, Andersen G,
Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L,
Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J,
Suarez BK, van Vierssen O, Frigge ML, Ober C, Hofker MH, Wijmenga C,
Christiansen C, Rader DJ, Palmer CNA, Rotimi C, Chan JCN, Pedersen O,
Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI,
Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir
U, Kong A, Stefansson K: Two variants on chromosome 17 confer prostate
cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat
Genet 39:977–983, 2007
25. Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, Daly A,
Lango H, Frayling TM, Neumann RJ, Sherva R, Blech I, Pharoah PD,
Palmer CNA, Kimber C, Tavendale R, Morris AD, McCarthy MI, Walker M,
Hitman G, Glaser B, Permutt MA, Hattersley AT, Wareham NJ, Barroso I:
Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet
39:951–953, 2007
26. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P,
Tuomi T, Gaudet D, Bostrom KB, Walker M, Hitman G, Hattersley AT,
McCarthy MI, Ardlie KG, Hirschhorn JN, Daly MJ, Frayling TM, Groop L,
Altshuler D: Evaluation of common variants in the six known maturity-
onset diabetes of the young (MODY) genes for association with type 2
diabetes. Diabetes 56:685–693, 2007
27. Frayling TM: Genome-wide association studies provide new insights into
type 2 diabetes aetiology. Nat Rev Genet 8:657–662, 2007
28. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnars-
dottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R,
Hinney A, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Schafer
H, Faruque M, Doumatey A, Zhou J, Wilensky RL, Reilly MP, Rader DJ,
Bagger Y, Christiansen C, Sigurdsson G, Hebebrand J, Pedersen O,
Thorsteinsdottir U, Gulcher JR, Kong A, Rotimi C, Stefansson K: Reﬁning
the impact of TCF7L2 gene variants on type 2 diabetes and adaptive
evolution. Nat Genet 39:218–225, 2007
29. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW,
MacDonald TM: The diabetes audit and research in Tayside Scotland
(DARTS) study: electronic record linkage to create a diabetes register.
DARTS/MEMO Collaboration. BMJ 315:524–528, 1997
30. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR,
Knowler WC, Nathan DM, Altshuler D: TCF7L2 polymorphisms and
progression to diabetes in the Diabetes Prevention Program. New Engl
J Med 355:241–250, 2006
31. Weedon MN: The importance of TCF7L2. Diabet Med 24:1062–1066, 2007
32. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-
analysis of genetic association studies supports a contribution of common
variants to susceptibility to common disease. Nat Genet 33:177–182, 2003
33. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio
K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M,
Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M,
Tuomilehto J: Sustained reduction in the incidence of type 2 diabetes by
lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
Lancet 368:1673–1679, 2006
34. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,
Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with
lifestyle intervention or metformin. New Engl J Med 346:393–403, 2002
35. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-
Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M,
Salminen V, Uusitupa M, Aunola S, Cepaitis Z, Moltchanov V, Hakumaki M,
Mannelin M, Martikkala V, Sundvall J: Prevention of type 2 diabetes
mellitus by changes in lifestyle among subjects with impaired glucose
tolerance. New Engl J Med 344:1343–1350, 2001
36. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ,
Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett
PH, Howard BV: Effects of diet and exercise in preventing NIDDM in
people with impaired glucose tolerance: the Da Qing IGT and Diabetes
Study. Diabetes Care 20:537–544, 1997
37. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L: Improved
identiﬁcation of patients with coronary artery disease by the use of new
lipid and lipoprotein biomarkers. Am J Cardiol 97:640–645, 2006
38. Kobberling J, Tillil H: Empirical risk ﬁgures for ﬁrst degree relatives of
non-insulin-dependent diabetics. In The Genetics of Diabetes Mellitus.
Kobberling J, Tattersall R, Eds. London, Academic Press, 1982, p. 201–210
39. Janssens AC, Moonesinghe R, Yang Q, Steyerberg EW, van Duijn CM,
Khoury MJ: The impact of genotype frequencies on the clinical validity of
genomic proﬁling for predicting common chronic diseases. Genet Med
9:528–535, 2007
40. Lu Q, Elston RC: Using the optimal receiver operating characteristic curve
to design a predictive genetic test, exempliﬁed with type 2 diabetes. Am J
Hum Genet 82:641–651, 2008
41. Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, Saloranta
C, Tuomi T, Groop L: Genetic prediction of future type 2 diabetes. PloS
Med 2:1299–1308, 2005
42. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren
P, Sjogren M, Ling C, Eriksson KF, Lethagen AL, Mancarella R, Berglund G,
Tuomi T, Nilsson P, Del Prato S, Groop L: Mechanisms by which common
variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest
117:2155–2163, 2007
43. Weedon MN, McCarthy MI, Hitman G, Walker M, Groves CJ, Zeggini E,
Rayner NW, Shields B, Owen KR, Hattersley AT, Frayling TM: Combining
information from common type 2 diabetes risk polymorphisms improves
disease prediction. PLoS Med 3:1877–1882, 2006
H. LANGO AND ASSOCIATES
DIABETES, VOL. 57, NOVEMBER 2008 3135